
Oblenio Bio raises $62M to advance autoimmune drug LBL-051 into clinical trials.
Oblenio Bio secured $62 million in a Series B funding round led by Pfizer Ventures to support clinical development of LBL-051, a tri-specific T-cell engager targeting autoimmune diseases. LBL-051 aims to reset the immune system by depleting B-cells a...

